Treatment of migraine attacks by transcutaneous electrical nerve stimulation in emergency department: A randomize controlled trial

Published:January 15, 2020DOI:



      The primary purpose of this trial is to evaluate the effectiveness of Transcutaneous Electrical Nerve Stimulation (TENS) therapy application in the emergency department.


      The patients were divided into 2 groups: a sham group, and a verum group. Patients in the verum group include those who use the device for the first time. Both groups were connected to visually indistinguishable devices. Both groups underwent therapy for a total of 20 min. Using the Visual Analog Scale (VAS), the patients' perceived changes in pain intensity were recorded at the 20th and 120th minutes after initiation therapy. After the 120th minute, patients' individual needs for additional treatment were assessed. Additionally, their self-reported well-being was assessed using a Likert-type verbal scale.


      In total 151 patients that were admitted to the emergency ward were assessed, with the sham and verum group being assigned 39 patients each from this pool. For the verum group the VAS change from 0 to 120 min was −65 ± 25 and for the sham group it was −9 ± 2 (p < 0.001). Verbal scores in the 120th minute were found to be 1.2 for sham group and 4.5 in the verum group (p < 0.001). Thirty patients (76.92%) in the sham group and 1 (2%) in the verum group had additional analgesic requirement after 120 min.


      TENS therapy is a fast-acting, effective therapy for the treatment of acute migraine in the emergency department.


      To read this article in full you will need to make a payment
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Emergency Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Ettlin D.A.
        The international classification of headache disorders, (beta version).
        Cephalalgia. 2013; 33: 629-808
        • Lozano R.
        • Naghavi M.
        • Foreman K.
        • Lim S.
        • Shibuya K.
        • Aboyans V.
        • et al.
        Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010.
        The Lancet. 2012; 380: 2095-2128
        • Mulleners W.
        • Chronicle E.
        Anticonvulsants in migraine prophylaxis: a Cochrane review.
        Cephalalgia. 2008; 28: 585-597
        • Fumal A.
        • Schoenen J.
        Current migraine management—patient acceptability and future approaches.
        Neuropsychiatr Dis Treat. 2008; 4: 1043
        • Fuller-Thomson E.
        • Hodgins G.A.
        Suicide attempts among those with migraine: findings from a nationally representative Canadian study.
        Arch Suicide Res. 2019; : 1-20
        • Watson T.
        Electrotherapy E-book: Evidence-based practice.
        Elsevier Health Sciences, 2008
        • Johnson M.I.
        • Bjordal J.M.
        Transcutaneous electrical nerve stimulation for the management of painful conditions: focus on neuropathic pain.
        Expert Rev Neurother. 2011; 11: 735-753
        • Vance C.G.T.
        • Rakel B.A.
        • Blodgett N.P.
        • DeSantana J.M.
        • Amendola A.
        • Zimmerman M.B.
        • et al.
        Effects of transcutaneous electrical nerve stimulation on pain, pain sensitivity, and function in people with knee osteoarthritis: a randomized controlled trial.
        Phys Ther. 2012; 92: 898-910
        • Piquet M.
        • Balestra C.
        • Sava S.L.
        • Schoenen J.E.
        Supraorbital transcutaneous neurostimulation has sedative effects in healthy subjects.
        BMC Neurol. 2011; 11: 135
        • Huskisson E.C.
        Measurement of pain.
        The lancet. 1974; 304: 1127-1131
        • Chou D.E.
        • Shnayderman Yugrakh M.
        • Winegarner D.
        • Rowe V.
        • Kuruvilla D.
        • Schoenen J.
        Acute migraine therapy with external trigeminal neurostimulation (ACME): a randomized controlled trial.
        Cephalalgia. 2019; 39: 3-14
        • CONSORT BT
        CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials.
        Ann Intern Med. 2010; 152
        • Steiner T.J.
        • Stovner L.J.
        • Vos T.
        GBD 2015: Migraine is the third cause of disability in under 50s.
        • Steiner T.
        • Paemeleire K.
        • Jensen R.
        • Valade D.
        • Savi L.
        • Lainez M.
        • et al.
        European principles of management of common headache disorders in primary care.
        J Headhache Pain. 2007; 8: S3-47
        • Lipton R.B.
        • Silberstein S.D.
        Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention.
        Headache. 2015; 55: 103-122
        • Marmura M.J.
        • Silberstein S.D.
        • Schwedt T.J.
        The acute treatment of migraine in adults: the American Headache Society evidence assessment of migraine pharmacotherapies.
        Headache. 2015; 55: 3-20
        • Colak S.
        • Erdogan M.O.
        • Afacan M.A.
        • Kosargelir M.
        • Aktas S.
        • Tayfur İ.
        • et al.
        Neuropsychiatric side effects due to a transdermal fentanyl patch: hallucinations.
        Am J Emerg Med. 2015; 33: 477.e1-477.e2
        • Schoenen J.
        Migraine treatment with external trigeminal nerve stimulation: current knowledge on mechanisms.
        Int Med Rev. 2017; 3: 786-791
        • Colak S.
        • Erdogan M.O.
        • Sekban H.
        • Afacan M.A.
        • Uras A.R.
        • Ibrahim A.
        • et al.
        Emergency diagnosis of upper gastrointestinal bleeding by detection of haemoglobin in nasogastric aspirate.
        J Int Med Res. 2013; 41: 1825-1829
        • Lipton R.B.
        • Baggish J.S.
        • Stewart W.F.
        • Codispoti J.R.
        • Fu M.
        Efficacy and safety of acetaminophen in the treatment of migraine: results of a randomized, double-blind, placebo-controlled, population-based study.
        Arch Intern Med. 2000; 160: 3486-3492
        • MacGregor E.A.
        • Dowson A.
        • Davies P.T.
        Mouth-dispersible aspirin in the treatment of migraine: a placebo-controlled study.
        Headache. 2002; 42: 249-255
        • Vecsei L.
        • Gallacchi G.
        • Sagi I.
        • Semjen J.
        • Tajti J.
        • Szok D.
        • et al.
        Diclofenac epolamine is effective in the treatment of acute migraine attacks. A randomized, crossover, double blind, placebo-controlled, clinical study.
        Cephalalgia. 2007; 27: 29-34
        • Codispoti J.R.
        • Prior M.J.
        • Fu M.
        • Harte C.M.
        • Nelson E.B.
        Efficacy of nonprescription doses of ibuprofen for treating migraine headache. A randomized controlled trial.
        Headache. 2001; 41: 665-679
        • Brandes J.L.
        • Kudrow D.
        • Stark S.R.
        • O’Carroll C.P.
        • Adelman J.U.
        • O’Donnell F.J.
        • et al.
        Sumatriptan-naproxen for acute treatment of migraine: a randomized trial.
        Jama. 2007; 297: 1443-1454
        • Friedman B.W.
        • Irizarry E.
        • Solorzano C.
        • Latev A.
        • Rosa K.
        • Zias E.
        • et al.
        Randomized study of IV prochlorperazine plus diphenhydramine vs IV hydromorphone for migraine.
        Neurology. 2017; 89: 2075-2082
        • Bloudek L.
        • Stokes M.
        • Buse D.
        • Wilcox T.
        • Lipton R.B.
        • Goadsby P.
        • et al.
        Cost of healthcare for patients with migraine in five European countries: results from the International Burden of Migraine Study (IBMS).
        J Headache Pain. 2012; 13: 361
        • Schoenen J.
        • Vandersmissen B.
        • Jeangette S.
        • Herroelen L.
        • Vandenheede M.
        • Gérard P.
        • et al.
        Migraine prevention with a supraorbital transcutaneous stimulator: a randomized controlled trial.
        Neurology. 2013; 80: 697-704
        • Magis D.
        • Sava S.
        • d’Elia T.S.
        • Baschi R.
        • Schoenen J.
        Safety and patients’ satisfaction of transcutaneous supraorbital neurostimulation (tSNS) with the Cefaly® device in headache treatment: a survey of 2,313 headache sufferers in the general population.
        J Headache Pain. 2013; 14: 95
        • Lipton R.B.
        • Buse D.C.
        • Serrano D.
        • Holland S.
        • Reed M.L.
        Examination of unmet treatment needs among persons with episodic migraine: results of the American Migraine Prevalence and Prevention (AMPP) study.
        Headache. 2013; 53: 1300-1311
        • Singh G.
        • Triadafilopoulos G.
        Epidemiology of NSAID induced gastrointestinal complications.
        The J Rheumatol Suppl. 1999; 56: 18-24
        • Llamas M.
        • Santiago D.
        • Navarro R.
        • Sánchez-Pérez J.
        • García-Diez A.
        Unusual allergic contact dermatitis produced by a transcutaneous electrical nerve stimulator.
        Contact Dermatitis. 2010; 62: 189-190
        • Ford K.S.
        • Shrader M.W.
        • Smith J.
        • Mclean T.J.
        • Dahm D.L.
        Full-thickness burn formation after the use of electrical stimulation for rehabilitation of unicompartmental knee arthroplasty.
        J Arthroplasty. 2005; 20: 950-953